Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
Saved in:
| Title: | Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial. |
|---|---|
| Authors: | Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Li T; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Ogayo ER; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Rahman T; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., DiLullo MK; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Patel A; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., El-Refai S; Personalis Inc., Fremont, California., Abbott C; Personalis Inc., Fremont, California., Li B; Personalis Inc., Fremont, California., Boyle SM; Personalis Inc., Fremont, California., Chen RO; Personalis Inc., Fremont, California., Desai NV; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Spring LM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Tung NM; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Sinclair N; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Faggen M; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Constantine M; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., King TA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Krop IE; Yale Cancer Center, New Haven, Connecticut., Tayob N; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Winer EP; Yale Cancer Center, New Haven, Connecticut., Parsons HA; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts. |
| Source: | JAMA oncology [JAMA Oncol] 2026 Jun 25. Date of Electronic Publication: 2026 Jun 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
